Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases

• Published in: Vaccine 2018-08, Vol.36 (32), p.4875-4879
• Main Authors: Harrison, Nicole, Poeppl, Wolfgang, Miksch, Manuel, Machold, Klaus, Kiener, Hans, Aletaha, Daniel, Smolen, Josef S., Forstner, Christina, Burgmann, Heinz, Lagler, Heimo
• Format: Article
• Language: English
• Subjects: Age; Antibiotics; Confidence intervals; Disease; Family physicians; Immunosuppressive agents; Inflammatory rheumatic disease; Influenza; Information sources; Patients; Population; Predictors; Questionnaires; Rheumatic diseases; Rheumatoid arthritis; Rheumatology; Seasons; Side effects; Statistical analysis; Vaccination; Vaccination rate; Vaccines
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2018.06.065

•Patients with rheumatic diseases have an influenza vaccination rate of 25.3%.•Higher age is significantly associated with an increased vaccination rate.•Therapy with biological DMARDs is associated with a positive vaccination status.•Recommendation of vaccination by a physician is the most significant predictor. Patients with inflammatory rheumatic diseases are at higher risk for influenza and current guidelines recommend vaccination for this group of patients. The aim of this study was to evaluate the vaccination coverage and predictors for influenza vaccination among patients with inflammatory rheumatic diseases. This survey was conducted at the outpatient rheumatology clinic at the Medical University of Vienna between July and October 2017. All patients diagnosed with an inflammatory rheumatic disease and receiving immunosuppressive therapy were asked to complete a questionnaire about their influenza vaccination status for 2016/17. 490 patients with rheumatic diseases completed a questionnaire (33% male, mean age 55.3 years). The influenza vaccination rate for the previous season was 25.3% (n = 124/490). Predictors for a positive influenza vaccination status were higher age (Adjusted Odds Ratio 5.0, 95% Confidence Interval 2.4–10.4) and treatment with biological disease-modifying antirheumatic drugs (AOR 2.0, 95% CI 1.3–3.1). Patients who received a recommendation for influenza vaccination by their general practitioner were significantly more likely to be vaccinated than those who did not (57% vs. 15%, AOR 6.6, 95% CI 4.1–10.8); even more so if they received a recommendation by their rheumatologist (62% vs. 19%, AOR 9.0, 95% CI 4.9–16.5). The main reasons for patients to decline influenza vaccination were fear of side effects (36%), concerns that vaccination might not be effective due to their immunosuppressed condition (38%) or that it might worsen the rheumatic disease (20%). A moderate influenza vaccination rate of 25.3% was detected among patients with inflammatory rheumatic diseases. Recommendation of the influenza vaccine by a physician exerts the most effective impact on a positive vaccination status.